REGULUS THERAPEUTICS INC (RGLS) Stock Price, Quote, News and Overview
NASDAQ:RGLS - Nasdaq - US75915K3095 - Common Stock - Currency: USD
RGLS Quote, Performance and Key Statistics
REGULUS THERAPEUTICS INC
NASDAQ:RGLS (1/30/2025, 4:20:20 PM)
After market: 0.99 -0.01 (-1%)1
+0.03 (+3.09%)
The current stock price of RGLS is 1 USD. In the past month the price decreased by -37.01%. In the past year, price decreased by -28.15%.
RGLS Latest News, Press Releases and Analysis
Here are the top movers in Wednesday's session.
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)
Topline data from an interim analysis of the fourth cohort of its Phase 1b Multiple-Ascending Dose (MAD) clinical trial showed continued mechanistic dose...
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...
RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q2 2024
RGLS stock results show that Regulus Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
RGLS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.34 | 310.40B | ||
| AMGN | AMGEN INC | 14.78 | 152.67B | ||
| GILD | GILEAD SCIENCES INC | 21.88 | 120.83B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 859.61 | 112.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.04 | 75.06B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.81B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.75B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.13B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.16B | ||
| NTRA | NATERA INC | N/A | 23.27B | ||
| BIIB | BIOGEN INC | 8.95 | 21.31B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.49B |
Related stock screener links
About RGLS
Company Profile
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. The company is headquartered in San Diego, California and currently employs 32 full-time employees. The company went IPO on 2012-10-04. The firm is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The firm is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.
Company Info
REGULUS THERAPEUTICS INC
4224 Campus Point Court, Suite 210
San Diego CALIFORNIA 92121 US
CEO: Joseph P. Hagan
Employees: 31
Company Website: https://www.regulusrx.com/
Investor Relations: http://ir.regulusrx.com/
Phone: 18582026300
RGLS FAQ
What is the stock price of RGLS?
The current stock price of RGLS is 1 USD.
What is the symbol for REGULUS THERAPEUTICS INC stock?
The exchange symbol of REGULUS THERAPEUTICS INC is RGLS and it is listed on the Nasdaq exchange.
On which exchange is RGLS stock listed?
RGLS stock is listed on the Nasdaq exchange.
Is RGLS a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for RGLS, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of RGLS.
Does RGLS stock pay dividends?
RGLS does not pay a dividend.
What is the Price/Earnings (PE) ratio of RGLS?
RGLS does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.07).
What is the Short Interest ratio of RGLS stock?
The outstanding short interest for RGLS is 2.63% of its float.
RGLS Technical Analysis
RGLS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RGLS. RGLS has a great financial health rating, but its profitability evaluates not so good.
RGLS Financial Highlights
Over the last trailing twelve months RGLS reported a non-GAAP Earnings per Share(EPS) of -1.07. The EPS decreased by 32.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.4% | ||
| ROE | -47.96% | ||
| Debt/Equity | 0 |
RGLS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to RGLS. The Buy consensus is the average rating of analysts ratings from 12 analysts.